cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Inovio Pharmaceuticals Inc
114 own
73 watching
Current Price
$1.91
$0.12
(6.7%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
476.52M
52-Week High
52-Week High
4
52-Week Low
52-Week Low
1.38
Average Volume
Average Volume
8.76M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization476.52M
icon52-Week High4
icon52-Week Low1.38
iconAverage Volume8.76M
iconDividend Yield--
iconP/E Ratio--
What does the Inovio Pharmaceuticals Inc do?
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus. The company's partners and collaborators include MedImmune, LLC, the Wistar Institute, University of Pennsylvania, Defense Advanced Research Projects Agency, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, the National Institutes of Health, HIV Vaccines Trial Network, National Cancer Institute, and U.S. Military HIV Research Program. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Read More
How much money does Inovio Pharmaceuticals Inc make?
News & Events about Inovio Pharmaceuticals Inc.
PR Newswire
1day ago
INOVIO Reports Inducement Grants Under Inducement Plan INOVIO Reports Inducement Grants Under Inducement Plan PR Newswire PLYMOUTH MEETING, Pa., Feb. 3, 2023 PLYMOUTH MEETING, Pa., Feb. 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing...
PR Newswire
2 months ago
While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat Subvariants While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat Subvariants PR Newswire PALM BEACH, Fla., Nov. 16, 2022 FinancialNewsMedia.com News Commentary PALM BEACH...
Ticker Report
4 months ago
Hennion Walsh Asset Management Inc. increased its stake in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO Get Rating) by 4.5% in the 2nd quarter, according to the company in its most recent filing with the Securities Exchange Commission. The fund owned 361,196 shares of the ...
Zolmax
5 months ago
WINTON GROUP Ltd increased its holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO Get Rating) by 30.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,156 shares of the biopharmaceutical ...
Frequently Asked Questions
Frequently Asked Questions
What is Inovio Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Inovio Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Inovio Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Inovio Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Inovio Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Inovio Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Inovio Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Inovio Pharmaceuticals Inc?
plus_minus_icon
What percentage is Inovio Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Inovio Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.91
$0.12
(6.7%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Mesoblast
Mesoblast
$3.66
$0.02 (0.55 %)
MacroGenics, Inc.
MacroGenics, Inc.
$5.59
$-0.33 (-5.57 %)
NanoString Technologies Inc
NanoString Technologies Inc
$12.08
$-0.49 (-3.90 %)
bluebird bio, Inc.
bluebird bio, Inc.
$6.65
$0.02 (0.30 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Mesoblast
Mesoblast
$3.66
$0.02 (0.55 %)
MacroGenics, Inc.
MacroGenics, Inc.
$5.59
$-0.33 (-5.57 %)
NanoString Technologies Inc
NanoString Technologies Inc
$12.08
$-0.49 (-3.90 %)
bluebird bio, Inc.
bluebird bio, Inc.
$6.65
$0.02 (0.30 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00